Cargando…
Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
Introduction: TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We have reported a retrospective analysis of newly diagnosed Chinese GBM patients who received TTFields/TMZ treatment and TMZ treatment from A...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570572/ https://www.ncbi.nlm.nih.gov/pubmed/36233722 http://dx.doi.org/10.3390/jcm11195855 |
_version_ | 1784810144138264576 |
---|---|
author | Chen, Chunjui Xu, Hao Song, Kun Zhang, Yi Zhang, Junyan Wang, Yang Sheng, Xiaofang Chen, Lingchao Qin, Zhiyong |
author_facet | Chen, Chunjui Xu, Hao Song, Kun Zhang, Yi Zhang, Junyan Wang, Yang Sheng, Xiaofang Chen, Lingchao Qin, Zhiyong |
author_sort | Chen, Chunjui |
collection | PubMed |
description | Introduction: TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We have reported a retrospective analysis of newly diagnosed Chinese GBM patients who received TTFields/TMZ treatment and TMZ treatment from August 2018 to May 2021 in Huashan hospital in Shanghai. Methods: Overall survival (OS) and progression-free survival (PFS) curves were constructed using the Kaplan–Meier method. A Cox proportional hazards regression model, propensity score matched data, and inverse probability of treatment weighting (IPTW) based on propensity score were used to assess the effect of TTFields and account for confounding factors. Results: In the preliminary analysis, the median PFS in TTFields/TMZ group was 16 months (95% CI, 9.6–24.6) versus 11 months (95% CI, 9–12) in TMZ group (p < 0.05). Median overall survival was 21.8 months (95% CI, 17.4-NA) with TTFields/TMZ versus 15 months (HR = 0.43; 95% CI, 13–18) with TMZ alone. The multivariate analysis identified surgery type, STUPP scheme, IDH status, and TTFields use as favorable prognostic factors. After PSM adjustment, the variate among the groups was similar, except that the methylation rate of MGMT promoter remained high in the TMZ group (12 v 32 months; p = 0.011). Upon IPTW Survival analysis, TTFields was associated with a significantly lower risk of death (HR = 0.19 in OS; 95% CI, 0.09–0.41) and progression (HR = 0.35; 95% CI 0.14–0.9) compared with TMZ group. Conclusion: In the final analysis of our single-center Chinese patients with glioblastoma, adding TTFields to temozolomide chemotherapy resulted in statistically significant improvement in PFS and OS. |
format | Online Article Text |
id | pubmed-9570572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95705722022-10-17 Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center Chen, Chunjui Xu, Hao Song, Kun Zhang, Yi Zhang, Junyan Wang, Yang Sheng, Xiaofang Chen, Lingchao Qin, Zhiyong J Clin Med Article Introduction: TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We have reported a retrospective analysis of newly diagnosed Chinese GBM patients who received TTFields/TMZ treatment and TMZ treatment from August 2018 to May 2021 in Huashan hospital in Shanghai. Methods: Overall survival (OS) and progression-free survival (PFS) curves were constructed using the Kaplan–Meier method. A Cox proportional hazards regression model, propensity score matched data, and inverse probability of treatment weighting (IPTW) based on propensity score were used to assess the effect of TTFields and account for confounding factors. Results: In the preliminary analysis, the median PFS in TTFields/TMZ group was 16 months (95% CI, 9.6–24.6) versus 11 months (95% CI, 9–12) in TMZ group (p < 0.05). Median overall survival was 21.8 months (95% CI, 17.4-NA) with TTFields/TMZ versus 15 months (HR = 0.43; 95% CI, 13–18) with TMZ alone. The multivariate analysis identified surgery type, STUPP scheme, IDH status, and TTFields use as favorable prognostic factors. After PSM adjustment, the variate among the groups was similar, except that the methylation rate of MGMT promoter remained high in the TMZ group (12 v 32 months; p = 0.011). Upon IPTW Survival analysis, TTFields was associated with a significantly lower risk of death (HR = 0.19 in OS; 95% CI, 0.09–0.41) and progression (HR = 0.35; 95% CI 0.14–0.9) compared with TMZ group. Conclusion: In the final analysis of our single-center Chinese patients with glioblastoma, adding TTFields to temozolomide chemotherapy resulted in statistically significant improvement in PFS and OS. MDPI 2022-10-03 /pmc/articles/PMC9570572/ /pubmed/36233722 http://dx.doi.org/10.3390/jcm11195855 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Chunjui Xu, Hao Song, Kun Zhang, Yi Zhang, Junyan Wang, Yang Sheng, Xiaofang Chen, Lingchao Qin, Zhiyong Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center |
title | Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center |
title_full | Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center |
title_fullStr | Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center |
title_full_unstemmed | Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center |
title_short | Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center |
title_sort | tumor treating fields combine with temozolomide for newly diagnosed glioblastoma: a retrospective analysis of chinese patients in a single center |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570572/ https://www.ncbi.nlm.nih.gov/pubmed/36233722 http://dx.doi.org/10.3390/jcm11195855 |
work_keys_str_mv | AT chenchunjui tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter AT xuhao tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter AT songkun tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter AT zhangyi tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter AT zhangjunyan tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter AT wangyang tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter AT shengxiaofang tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter AT chenlingchao tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter AT qinzhiyong tumortreatingfieldscombinewithtemozolomidefornewlydiagnosedglioblastomaaretrospectiveanalysisofchinesepatientsinasinglecenter |